Clinical findings show association between nadunolimab and lower incidence and later onset of CIPN Preclinical data show ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

Recent investigation focuses on the effects of BRCA1 and BRCA2 tumor pathogenic variants (tPVs) within the parameters of two ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...

The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.

Novocure (NVCR) announced that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields therapy for ...

In patients with bladder cancer, lactylation score may predict survival and efficacy of immune checkpoint inhibitor treatment, according to researchers.